Gilead announces new clinical research data on hepatitis B functional cure new drug GS-9688
-
Last Update: 2020-06-07
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
recently, Gilead, thegiant ofpharmaceutical(http:// released new clinical research data on the functional curethe new drug(http://Gs-9688( selgantolimod)About GS-9688
GS-9688 is an oral, selective toll-like receptor 8 (TLR8) small molecular agonistin a multicenter, randomized, double-blind Phase II study of 48 patients with chronic HBV who had achieved virological inhibition, GS-9688 (once-a week oral oraldrug(http://(OAVs) was well tolerated during extended administration and showed pharmacodynamic activity on dose dependenceThe clinical activity of GS-9688 was also assessed: 5% of patients treated with GS-9688 decreased in levels of hepatitis B surface antigen (HBsAg) or HBeE antigen (HBeAg) at the 24th week of treatmentThese data support ongoing GS-9688 research and new combinations designed to enable functional cure of HBVThe safety and efficacy of GS-9688, a research compound that has not been approved by the U.SFDA (http:// or any other regulatory agency
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
